Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Authors: Liu, Pei; Liu, Hongbo; Sun, Qi; Liang, Hao; Li, Chunmei; Deng, Xiaobing; Liu, Ying; Lai, Luhua
SARS-CoV-2 3C like protease is the main protease of SARS-CoV-2 and has been considered as one of the key targets for drug discovery against COVID-19. We identified several N-substituted isatin compounds as potent SARS-CoV-2 3C-like protease inhibitors. The three most potent compounds inhibit SARS-CoV-2 3C-like protease with IC50's of 45 nM, 47 nM and 53 nM, respectively. Our study indicates that N-substituted isatin compounds have the potential to be developed as broad-spectrum anti-coronavirus drugs. (C) 2020 Elsevier Masson SAS. All rights reserved.
Abrupt Deterioration of COVID-19 Patients and Spreading of SARS COV-2 Virions in the Lungs
ANNALS OF BIOMEDICAL ENGINEERING
Authors: Filipovic, N.; Saveljic, I.; Hamada, K.; Tsuda, A.
A unique feature of COVID-19 interstitial pneumonia is an abrupt progression to respiratory failure. Our calculation shows that this abrupt deteriorate may be caused by a sudden shift in the spread of virus-laden bioaerosols through the airways to many different regions of the lungs from the initial site of infection.